Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Efavirenz (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Acronyms ESCALE
- 24 May 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 06 Jul 2013 New trial record